A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature Immunology

• Publication date

  2013-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ni.2762PMID 24240160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response

  2013cited by this paper
• Treg and CTLA-4: Two intertwining pathways to immune tolerance

  2013cited by this paper
• T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion

  2013cited by this paper
• Tumor immunotherapy directed at PD-1.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut

  2012cited by this paper
• STAT5 Protein Negatively Regulates T Follicular Helper (Tfh) Cell Generation and Function*

  2012cited by this paper
• The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood

  2012cited by this paper
• Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

  2012cited by this paper
• STAT5 is a potent negative regulator of TFH cell differentiation

  2012cited by this paper
• Foxp3(+) follicular regulatory T cells control the germinal centre response

  2012cited by this paper
• Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

  2011cited by this paper
• Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

  2011cited by this paper
• Foxp3+ follicular regulatory T cells control T follicular helper cells and the germinal center response

  2011cited by this paper
• Programmed Cell Death 1 Suppresses B-1b Cell Expansion and Long-Lived IgG Production in Response to T Cell-Independent Type 2 Antigens

  2011cited by this paper
• Regulation of the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells

  2011cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

  2011cited by this paper
• Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1

  2011cited by this paper
• Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family

  2011cited by this paper
• Faculty Opinions recommendation of Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.

  2011cited by this paper
• Faculty Opinions recommendation of Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions.

  2011cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

  2010cited by this paper
• IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses

  2010cited by this paper
• IL-21 regulates germinal center B cell differentiation and proliferation through a B cell–intrinsic mechanism

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• PD-1 deficiency results in the development of fatal myocarditis in MRL mice.

  2010cited by this paper
• PD-1+ memory phenotype CD4+ T cells expressing C/EBPα underlie T cell immunodepression in senescence and leukemia

  2009cited by this paper
• PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo1

  2009cited by this paper
• Severe functional impairment and elevated PD‐1 expression in CD1d‐restricted NKT cells retained during chronic HIV‐1 infection

  2009cited by this paper
• Autoimmune Dilated Cardiomyopathy

  2008cited by this paper
• Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

  2008cited by this paper
• TGF-beta: a master of all T cell trades.

  2008cited by this paper
• NFATc1 Regulates PD-1 Expression upon T Cell Activation1

  2008cited by this paper
• The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice

  2008cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Essential Role of IL-21 in B Cell Activation, Expansion, and Plasma Cell Generation during CD4+ T Cell-B Cell Collaboration1

  2007cited by this paper
• Role of CXCR5 and CCR7 in Follicular Th Cell Positioning and Appearance of a Programmed Cell Death Gene-1High Germinal Center-Associated Subpopulation1

  2007cited by this paper
• Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects.

  2006cited by this paper
• TGF-beta and CD4+CD25+ regulatory T cells.

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.

  2005cited by this paper
• Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b −/− Pdcd1 −/− mice

  2005cited by this paper
• PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

  2004cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• Costimulatory B 7-H 1 in renal cell carcinoma patients : Indicator of tumor aggressiveness and potential therapeutic target

  2004cited by this paper
• Structural and functional analysis of the costimulatory receptor programmed death-1.

  2004cited by this paper
• PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

  2004cited by this paper
• SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

  2003cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T‐enriched splenocytes

  2003cited by this paper
• Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes.

  2003cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

  2002cited by this paper
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

  2002cited by this paper
• Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• B1 cells: similarities and differences with other B cell subsets.

  2001cited by this paper
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001cited by this paper
• Erratum: Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses (Nature (2001) 410 (608-611))

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

  2000cited by this paper
• T-Independent immune response: new aspects of B cell biology.

  2000cited by this paper
• Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.

  1999cited by this paper
• Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

  1999cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.

  1998cited by this paper
• Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

  1997cited by this paper
• Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.

  1997cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

  1996cited by this paper
• Tolerance and cancer: a critical issue in tumor immunology.

  1996cited by this paper
• Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.

  1993cited by this paper
• Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

  1992cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper

• Combination therapy for colorectal cancer with anti-PD-L1 and cancer vaccine: A multiscale mathematical model of tumor-immune interactions.

  2026influential citation
• Active aldehydes accelerate CD8+ T cell exhaustion by metabolic alteration in the tumor microenvironment

  2026cites this paper
• Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape

  2026cites this paper
• Decoding C‑SH2 Domain/Peptide Interactions in SH2 Domain-Containing Tyrosine Phosphatase 2: A Molecular Framework for Rational Inhibitor Design

  2026cites this paper
• In search of a targetable immune profile for acute myeloid leukemia.

  2025cites this paper
• A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies

  2025cites this paper
• Paeonol alleviates PD-1 deficiency-induced anxiety-like behaviors through reversing the neurotransmitter metabolic disorders in spleen-brain axis.

  2025cites this paper
• Patterns of pembrolizumab use for recurrent cervical cancer.

  2025cites this paper
• Wip1 inhibitor CCT007093 alleviates immune exhaustion of lymphocytes via p65 NF-κB and YY1 in chronic hepatitis B virus infection in mice

  2025cites this paper
• Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification

  2025cites this paper
• Therapeutic potential of targeting LAG-3 in cancer

  2025cites this paper
• 3-in-one PD-1CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential

  2025cites this paper
• Chemotherapy modulates PD-L1 expression and its combination with immune checkpoint blockade requires precision.

  2025cites this paper
• Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review

  2025cites this paper
• CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis

  2025cites this paper
• Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy

  2025cites this paper
• High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer.

  2025cites this paper
• Enhancing T-Cell Infiltration and Immunity in Solid Tumors via DNA Nanolinker-Mediated Monocyte Hitchhiking.

  2025cites this paper
• Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies

  2025cites this paper
• GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint

  2025cites this paper
• A Case of Rapidly Progressive Pneumonitis Induced by Nivolumab in Metastatic Gastroesophageal Adenocarcinoma: Challenges in Diagnosis and Management

  2025cites this paper
• Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• Development of Novel Short Peptide Inhibitor Targeted to Immune Checkpoint PD-1 LBD

  2025cites this paper
• Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC

  2025cites this paper
• CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis

  2025cites this paper
• T Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?

  2025cites this paper
• PD-1 deficiency disrupts in vivo neural activity in mouse Hippocampus and cortex.

  2025cites this paper
• The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care.

  2025cites this paper
• Targeting the Exon2 splice cis-element in PD-1 and its effects on lymphocyte function

  2025cites this paper
• Modulating checkpoint molecules in inflammatory bowel diseases as a new therapeutic strategy: a narrative review.

  2025cites this paper
• Discovery of SA-8 as a potent SHP2-AUTAC degrader in cancer therapy.

  2025cites this paper
• Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer.

  2025cites this paper
• Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer

  2025cites this paper
• Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

  2025cites this paper
• PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity

  2025cites this paper
• LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3

  2025cites this paper
• Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion.

  2025cites this paper
• Programmed Cell Death‐1 and Programmed Cell Death Ligand‐1 in Childhood Acute B‐Lymphoblastic Leukemia: Expression and Significance as Biomarker

  2025cites this paper
• Management of metastatic melanoma with combinations including PD-1 inhibitors

  2025cites this paper
• B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

  2025cites this paper
• Contemporary Approaches to Immunotherapy of Solid Tumors

  2024cites this paper
• The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review

  2024cites this paper
• Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches

  2024cites this paper
• Critical role of the gut microbiota in immune responses and cancer immunotherapy

  2024cites this paper
• Quantitative cancer-immunity cycle modeling for predicting disease progression in advanced metastatic colorectal cancer

  2024cites this paper
• SGLT2 inhibition eliminates senescent cells and alleviates pathological aging

  2024cites this paper
• Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment

  2024cites this paper
• The Role of Immune Check Point Gene Expression of Pd-1 and Tim-3 in Patients with Acute Myeloid Leukemia

  2024cites this paper
• The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

  2024cites this paper
• SURVIVIN IN SYNERGY WITH BAF/SWI COMPLEX BINDS BIVALENT CHROMATIN REGIONS AND ACTIVATES DNA DAMAGE RESPONSE IN CD4+ T CELLS

  2024cites this paper
• The roles of ABCB1/P-glycoprotein drug transporters in regulating gut microbes and inflammation: insights from animal models, old and new

  2024cites this paper
• The comprehensive landscape of prognosis, immunity, and function of the GLI family by pan-cancer and single-cell analysis

  2024cites this paper
• The prognostic biomarker TPGS2 is correlated with immune infiltrates in pan-cancer: a bioinformatics analysis

  2024cites this paper
• Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

  2024cites this paper
• PD-1 endocytosis unleashes the cytolytic potential of check-point blockade in tumor immunity

  2024cites this paper
• Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction.

  2024cites this paper
• Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer

  2024cites this paper
• Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma

  2024cites this paper
• Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis

  2024cites this paper
• Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns

  2024cites this paper
• Immune escape of avian oncogenic Marek’s disease herpesvirus and antagonistic host immune responses

  2024cites this paper
• Peripheral-central network analysis of cancer cachexia status accompanied by the polarization of hypothalamic microglia with low expression of inhibitory immune checkpoint receptors

  2024cites this paper
• 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis

  2024cites this paper
• Clinical features and prognosis of conjunctival melanoma in Japanese patients

  2024cites this paper
• Artificial intelligence in immunotherapy PET/SPECT imaging

  2024cites this paper
• Mapping the epitope of PD-L1 to the paratope of the antibody durvalumab using molecular dynamics simulation.

  2024cites this paper
• Clinical Implementation of MicroRNAs in Cancer Immunology

  2024cites this paper
• Pneumocystis jirovecii Pneumonia in a Patient With Localized Mycosis Fungoides Not Receiving Immunosuppressive Treatment

  2024cites this paper
• Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients

  2024cites this paper
• Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer

  2024cites this paper
• PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation - therapeutic implications for autoimmunity.

  2024cites this paper
• Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma

  2024cites this paper
• Challenges and advances of immune checkpoint therapy

  2024cites this paper
• PD‐1+CD8+ T Cell‐Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease

  2024cites this paper
• Neurological complications of immune checkpoint inhibitors: a practical guide

  2024cites this paper
• Engineering antibodies with cancer‐associated binding sites

  2024cites this paper
• PET radiomics in lung cancer: advances and translational challenges

  2024cites this paper
• Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer

  2024cites this paper
• Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study

  2024cites this paper
• Bivalent chromatin accommodates survivin and BRG1/SWI complex to activate DNA damage response in CD4+ cells

  2024cites this paper
• The effect of immunotherapy PD-1 blockade on acute bone cancer pain: Insights from transcriptomic and microbiomic profiling.

  2024cites this paper
• B7‐H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion

  2024cites this paper
• Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy

  2024cites this paper
• Expression patterns of immune checkpoint proteins and Plasmodium falciparum‐induced cytokines in chronic hepatitis B virus‐infected and uninfected individuals: A cross‐sectional study

  2024cites this paper
• Pancreatic ductal adenocarcinoma microenvironment: soluble factors and cancer associated fibroblasts as modulators of NK cell functions.

  2024cites this paper
• Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma

  2024cites this paper
• Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors.

  2024cites this paper
• Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer

  2024cites this paper
• Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review

  2024cites this paper
• Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications

  2024influential citation
• Th17/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target

  2024cites this paper
• Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy

  2023cites this paper
• The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors

  2023cites this paper
• Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy

  2023cites this paper
• The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer

  2023cites this paper
• ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers

  2023cites this paper
• Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.

  2023cites this paper
• Vitreous metastasis from cutaneous melanoma: diagnosis and management

  2023cites this paper
• Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.

  2023cites this paper